The ATP2A1 antibody targets the ATP2A1 gene product, also known as sarcoplasmic/endoplasmic reticulum calcium ATPase 1 (SERCA1), a critical enzyme responsible for actively transporting calcium ions from the cytosol into the sarcoplasmic reticulum (SR) in skeletal muscle cells. This calcium reuptake is essential for muscle relaxation and maintaining calcium homeostasis during contraction-relaxation cycles. SERCA1. encoded by ATP2A1. is predominantly expressed in fast-twitch skeletal muscle fibers, distinguishing it from other SERCA isoforms (e.g., SERCA2 in cardiac/smooth muscle).
ATP2A1 antibodies are widely used in research to study skeletal muscle physiology, pathologies, and disorders linked to SERCA1 dysfunction. Mutations in ATP2A1 are associated with rare genetic conditions like Brody myopathy, characterized by impaired muscle relaxation and exercise-induced stiffness. Researchers employ these antibodies in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to analyze SERCA1 expression levels, localization, and structural abnormalities in muscle tissues or cell models.
Additionally, ATP2A1 antibodies aid in exploring the role of calcium dysregulation in muscular dystrophies, aging-related sarcopenia, and metabolic myopathies. Their specificity for SERCA1 makes them valuable tools for distinguishing skeletal muscle-specific calcium handling mechanisms from other isoforms. Commercial ATP2A1 antibodies are typically validated across species, including human, mouse, and rat, ensuring broad applicability in preclinical and clinical research.